iBio (IBIO) Retained Earnings (2011 - 2026)
iBio (IBIO) posted quarterly Retained Earnings of -$354.7 million for Q1 2026, down 8.44% year-over-year from -$387.4 million in Q1 2025, and down 2.23% quarter-over-quarter from -$346.9 million in Q4 2025.
iBio (IBIO) Retained Earnings (2011 - 2026) Analysis & Trends
iBio (IBIO) has reported Retained Earnings for 16 consecutive years, with -$354.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 8.44% year-over-year to -$354.7 million; the TTM figure through Mar 2026 stood at -$354.7 million (down 8.44% YoY), while the FY2025 annual figure was -$332.2 million, down 5.86% from the prior year.
- Retained Earnings retreated to -$354.7 million in Q1 2026 per IBIO's latest filing, from -$346.9 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$213000.0 in Q2 2022 and bottomed at -$354.7 million in Q1 2026.
- Historically, Retained Earnings has averaged -$271.2 million across 5 years, with a median of -$306.1 million in 2024.
- Annual changes were most pronounced in 2022 — Retained Earnings soared 99.88% — and 2023, when it plunged 135552.58%.
- iBio's Retained Earnings stood at -$275.6 million in 2022, then fell by 9.9% to -$302.9 million in 2023, then fell by 6.37% to -$322.2 million in 2024, then dropped by 7.68% to -$346.9 million in 2025, then slipped by 2.23% to -$354.7 million in 2026.
- Business Quant data shows IBIO's Retained Earnings at -$354.7 million in Q1 2026, -$346.9 million in Q4 2025, and -$337.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | iBio | 172.22 Mn | 172.22 Mn | - | -354.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -354.67 Mn |
| Dec 31, 2025 | -346.94 Mn |
| Sep 30, 2025 | -337.94 Mn |
| Jun 30, 2025 | -332.22 Mn |
| Mar 31, 2025 | -327.06 Mn |
| Dec 31, 2024 | -322.20 Mn |
| Sep 30, 2024 | -317.84 Mn |
| Jun 30, 2024 | -313.85 Mn |
| Mar 31, 2024 | -306.07 Mn |
| Dec 31, 2023 | -302.90 Mn |
| Sep 30, 2023 | -294.69 Mn |
| Jun 30, 2023 | -288.94 Mn |
| Mar 31, 2023 | -282.91 Mn |
| Dec 31, 2022 | -275.61 Mn |
| Sep 30, 2022 | -223,000.00 |
| Jun 30, 2022 | -213,000.00 |
| Mar 31, 2022 | -206.88 Mn |
| Dec 31, 2021 | -194.49 Mn |
| Sep 30, 2021 | -182.57 Mn |
| Jun 30, 2021 | -63,000.00 |